Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03864679 Completed - Healthy Clinical Trials

Investigation of Fat Oxidation During Moderate Versus Vigorous Intensity Exercise

Start date: June 18, 2018
Phase: N/A
Study type: Interventional

Exercise is widely suggested as an important lifestyle change for weight loss, however, the optimal level of intensity moderate versus vigorous remains unclear. It is known that in athletes, during very high-intensity exercise, fat oxidation is decreased and energy is gained mainly from carbohydrate utilization. The aim of this study is to find an optimal workload based on fat oxidation rate during exercise in volunteers with a sedentary lifestyle.

NCT ID: NCT03860506 Completed - Healthy Clinical Trials

Study Evaluating the Effects of PSI-697 on Platelets in Subjects Who Smoke

Start date: April 1, 2008
Phase: Phase 1
Study type: Interventional

This is a single dose inpatient and outpatient study to test whether an effect on the ability of platelets to stick to white blood cells in subjects who smoke.

NCT ID: NCT03855839 Completed - Healthy Clinical Trials

The Effect of Posture Shirts on Posture During Functional Tasks

Start date: April 26, 2018
Study type: Observational

This study investigates the effect of a posture shirt on posture during functional tasks such as office work.

NCT ID: NCT03855306 Completed - Healthy Clinical Trials

A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. )

Start date: June 30, 2018
Phase: Phase 1
Study type: Interventional

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Glibenclamide from Glibesyn 5 mg tablets (Manufactured by Medochemie LTD Cyprus) and Daonil 5 mg tablets (Sanofi-Aventis Cyprus Ltd. ) after a single oral dose administration of each to healthy adults under fasting conditions

NCT ID: NCT03852446 Completed - Healthy Clinical Trials

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

Start date: March 5, 2018
Phase: Early Phase 1
Study type: Interventional

This 2-part study will assess the effect of formulation and food on the pharmacokinetics of Indoximod in healthy volunteers. Part 1 is a randomized single ascending dose study of indoximod salt formulation to characterize the PK profile and determine the safety and tolerability of each dose in healthy male volunteers. Part 2 is an open-label, randomized, 3-period, 3-way crossover study. Participants will receive single doses of Indoximod base or salt formulation, in the fasted or fed state.

NCT ID: NCT03846739 Completed - Healthy Clinical Trials

Dose-dependent Effects of Oxytocin on the Amygdala and Reward System

Start date: April 3, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether effects of intranasal oxytocin on amygdala and reward system responses vary as a function of treatment dose in women in comparison to men.

NCT ID: NCT03844958 Completed - Healthy Clinical Trials

Effect of Red Furu Consumption on Serum Vitamin B12 and Homocysteine Concentration In Healthy Young Volunteers

Start date: June 15, 2017
Phase: N/A
Study type: Interventional

The aim of the present study is to investigate the effect of red furu (Chinese fermented soybean product) consumption on serum vitamin B12, Homocysteine concentration and other cardio-metabolic risk factors in healthy young volunteers.

NCT ID: NCT03840330 Completed - Healthy Clinical Trials

High-intensity Training for Improving Physical Performance of Aged Women

Start date: December 20, 2015
Phase: N/A
Study type: Interventional

This study evaluates the adaptations on the functional capacity and cardiovascular in elderly after a physical activity program circuit training. The participants were divided into three groups: Circuit training based on high-intensity interval training group (HIICT), Circuit training at moderate intensity group (MICT) and Control group (CG).

NCT ID: NCT03838822 Completed - Healthy Clinical Trials

Kinetics of Metabolic Cofactors in NAFLD

Start date: September 1, 2018
Phase: Early Phase 1
Study type: Interventional

There is a strong correlation between major adverse health consequences of obesity and development of non-alcoholic fatty liver disease (NAFLD). NAFLD is characterized by abnormal hepatic accumulation of triglycerides and other lipids. It has become a worldwide health problem that accelerates cirrhosis, type 2 diabetes mellitus (T2DM), and especially premature cardiovascular morbidity and mortality. The plasma level of glutathione (GSH) is typically depleted in individuals with metabolism related disorders. However, cellular GSH levels cannot be increased by supplementing GSH and it must be synthesized within the liver either de novo or by salvation pathway. The level of GSH is not enough to maintain and regulate the thiol redox status of the liver in subjects with high hepatic steatosis at fasting stage due to the depletion of glycine. Glycine can be synthesized via the interconversion of serine. It has been shown that the serine synthesis is downregulated in patients with NAFLD and supplementation of serine has attenuated alcoholic fatty liver by enhancing homocysteine metabolism in mice and rats. Depleted liver glutathione is also restored by the administration of N-acetylcystein as in acetaminophen poising. L-carnitine and nicotinamide that both stimulate the transfer of fatty acids from cytosol to mitochondria have been identified as two additional cofactors that are depleted in patients with NAFLD. In this study, the kinetics in blood of pivotal metabolic cofactors, serine, L-carnitine, N-acetylcystein and nicotinamide after single and simultaneous dietary supplementation, are measured.

NCT ID: NCT03836222 Completed - Healthy Clinical Trials

Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects

Start date: February 26, 2018
Phase: Phase 1
Study type: Interventional

This was a Phase I, single centre, open-label, non-randomised study and was designed to be conducted in up to 2 parts. The purpose of Part 1 was to identify a MR formulation of PCS499 that would provide an optimal dosing regimen in patients. The purpose of Part 2 of the study was to generate repeat dose information for the selected MR formulation of PCS499 in order to provide additional PK information for future patient studies.